Vor, Abound Bio to develop multitargeted CAR T therapies

By The Science Advisory Board staff writers

June 11, 2021 -- Vor Biopharma has entered into a multiyear strategic collaboration and license agreement with Abound Bio to research both single- and multitargeted chimeric antigen receptor (CAR) T-cell treatments.

Under the terms of the agreement, the CAR T treatments will be used in combination with Vor's engineered hematopoietic stem cell platform, which shields the patient from unwanted side effects. The goal is to generate novel treatment systems for patients with acute myeloid leukemia and other forms of blood cancer, the companies said.

Financial terms of the deal were not disclosed.

Yufan, Abound Bio to develop CAR T cell therapies
Yufan Biotechnologies and Abound Bio have signed a multiyear agreement to find antibodies to direct chimeric antigen receptor (CAR) T cells against cancer...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter